Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy

  • Authors:
    • Taek-Keun Nam
    • Ji-Shin Lee
    • Hyeong-Rok Kim
    • Sung-Ja Ahn
    • Ju-Young Song
    • Mee S. Yoon
  • View Affiliations

  • Published online on: January 1, 2010     https://doi.org/10.3892/ol_00000004
  • Pages: 23-29
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study evaluated the expression of p53, pRb, hMLH1 and MDM2 prior to preoperative chemoradiotherapy (CRT) in patients with rectal cancer, and attempted to determine any correlation with treatment outcome. Forty-five patients with available pretreatment biopsy tissues and who received preoperative CRT were enrolled in this study. Preoperative CRT consisted of a median 50.4 Gy and 2 cycles of concurrent administration of 5-fluorouracil + leucovorin. Surgery was performed approximately seven weeks after CRT. Protein expression in formalin-fixed paraffin-embedded biopsy specimens was assessed by immunohistochemistry. A positive expression of p53, pRb, hMLH1 and MDM2 was found in 40, 46.7, 40 and 66.7% of the tissue specimens, respectively. The 5-year overall (OS), disease-free (DFS) and locoregional recurrence-free survival (LRFS) rates for patients included in the study were 71.3, 66.1 and 60.9%, respectively. p53 expression presented a significantly different OS (positive vs. negative, 45.8 vs. 86.2%; p=0.02). However, the expression of pRb, hMLH1 and MDM2 was not significant for OS. The expression of p53 was a borderline significant prognostic factor for DFS and for LRFS. Age, p53 and MDM2 expression were significant factors in the multivariate analysis performed for OS with 12 covariates, including 8 clinicopathological parameters and 4 proteins. No significant factor affected DFS or LRFS in the multivariate analysis. We suggest that the expression of p53 is a potential marker of survival. Determinations of this protein expression may be useful for selecting candidates from rectal cancer patients for more tailored treatment.
View Figures
View References

Related Articles

Journal Cover

January-February 2010
Volume 1 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nam T, Lee J, Kim H, Ahn S, Song J and Yoon MS: Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy . Oncol Lett 1: 23-29, 2010
APA
Nam, T., Lee, J., Kim, H., Ahn, S., Song, J., & Yoon, M.S. (2010). Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy . Oncology Letters, 1, 23-29. https://doi.org/10.3892/ol_00000004
MLA
Nam, T., Lee, J., Kim, H., Ahn, S., Song, J., Yoon, M. S."Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy ". Oncology Letters 1.1 (2010): 23-29.
Chicago
Nam, T., Lee, J., Kim, H., Ahn, S., Song, J., Yoon, M. S."Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy ". Oncology Letters 1, no. 1 (2010): 23-29. https://doi.org/10.3892/ol_00000004